Monday, August 31, 2026

Tilray Soars 23% In Last 10 Sessions: Is The Sky The Limit?

ViaNews Editorial Team

September 13, 2023

Tilray Soars 23% In Last 10 Sessions: Is The Sky The Limit?

(VIANEWS) - Tilray (TLRY) shares have seen their shares surge 23.33% over 10 sessions from EUR2.4 to EUR2.96, as of 14:13 EST Wednesday afternoon, following an upward trend in previous sessions. Meanwhile, the NASDAQ rose 0.5% to EUR13,842.82, following suit. Tilray closed at EUR2.91, 43.16% below its 52-week high of EUR5.12.

About Tilray

Tilray Brands, Inc. is a world leader in medical cannabis with operations throughout North and South America, Europe, Australia and New Zealand. This company cultivates, processes and distributes an assortment of medical cannabis products through four business segments: Cannabis Business, Distribution Business, Beverage Alcohol Business and Wellness Business. Tilray Brands provides more than medical and adult-use cannabis products; we also offer pharmaceutical, wellness, beverage alcohol products and hemp-based food and wellness solutions. Tilray sells their products under many distinct brand names, including Tilray, Aphria, Broken Coast Symbios B!NGO The Batch Dubon Good Supply Solei Chowie Wowie Canaca Riff SweetWater Breckenridge Distillery Alpine Beer Company Green Flash to name just a few. Tilray Brands provides its products to retailers, wholesalers, patients, physicians, hospitals, pharmacies, researchers, governments and consumers, directly as well as through retail. Headquartered in Leamington, Canada and originally known as Tilray Inc before transitioning into Tilray Brands Inc in January 2022.

Yearly Analysis

Here is a concise investment outlook for Tilray stock: Tilray (TIL.TO) stock is currently trading at EUR2.96, significantly below its 52-week high of EUR5.12 but above its low point of EUR1.50, suggesting some level of fluctuation over the past year. Tilray anticipates sales growth of 16.2% this year and 9.8% next year, suggesting moderate expansion over the coming years. Tilray's EBITDA stands at 2.85, which indicates a relatively healthy profit margin. However, EBITDA isn't a universal metric and may differ depending on which company calculates it; thus it's wise to take other financial metrics into consideration as well. Overall, Tilray's stock has experienced some volatility over the past year; however, their projected sales growth and healthy profit margin suggest they may make for a good long-term investment opportunity for those who are comfortable taking moderate risk. Before making your decision though, be sure to conduct extensive research.

Technical Analysis

Tilray Inc. (OTC:TLRY) has seen its stock prices decline significantly, currently sitting above its 50-day moving average of EUR2.02 and well beyond its 200-day moving average of EUR2.63. However, trading volumes have decreased considerably; today's volume being 24.46% below average volumes at 29,646,900. The stock has demonstrated low levels of volatility over the past week, month, and quarter; its current intraday variation average stands at 3.65%, 1.44% and 5.01% respectively. However, its highest average volatility amplitude was recorded as 4.10% over those three periods - this includes both weekly and monthly variations with respect to each. According to the stochastic oscillator, which provides a measure of overbought and oversold conditions, Tilray stock appears to be oversold (=20), suggesting it may be undervalued and poised for a price rebound. Tilray stock prices have recently seen prices that are above their moving averages but trading below its average volume. Furthermore, its volatility levels have been low and is considered oversold, suggesting an investment opportunity for Tilray. Before making any decision to purchase shares in Tilray it is vital that thorough research and professional advice is undertaken prior to making decisions about investment decisions.

Quarter Analysis

Based on this data, Tilray's current quarter sales growth stands at 13.6% while growth estimates for both this and next quarters stand at 61.55% and 54.5%, respectively. Year-on-year quarterly revenue growth stands at 20.1% with current revenues totalling 627.12M. Investors should take note that Tilray has experienced rapid sales growth over recent quarters, with projections for future quarters looking promising as well. This may signal an upward trend in its business performance; however, investors should also carefully consider other aspects such as profitability, competitive landscape and overall market conditions when making investment decisions. Researching Tilray's growth trajectory and aligning it with your investment goals are both key steps in making an informed decision about investing. Furthermore, speaking to a financial advisor before making decisions is always recommended.

Equity Analysis

Tilray currently reports an EPS of EUR-2.07 over its trailing twelve month period, which indicates they reported losses during that timeframe. Investors need this information in order to gain insight into Tilray's financial health and profitability. Additionally, Tilray's Return on Equity (ROE) over the twelve trailing months stands at an unfavorable -37.14%. ROE measures how profitable a business is relative to shareholder's equity; when negative ROE occurs it is indicative of underperformance compared with shareholder investments made. Overall, Tilray may not be an attractive investment opportunity right now; investors should conduct additional research into its finances, industry trends, and growth prospects prior to making any definitive investment decisions.

More news about Tilray (TLRY).

ViaNews Editorial Team

Via News Editorial Team delivers comprehensive financial news coverage and market analysis from journalists around the world. Our team specializes in data journalism and in-depth reporting on stock markets, business developments, and economic trends.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Enterprise AI's Trust Gap: Microsoft-Mistral Ecosystem Expansion Meets a Governance Deficit in Agentic Adoption
Microsoft is deepening its AI platform bet through simultaneous moves — expanding its Mistral partnership (Copilot Studio, Foundry, European infrastructure capacity) and deepening enterprise AI governance ties with Manulife — just as independent research (Google Cloud, VentureBeat, Box) shows enterprises racing toward agentic AI adoption (100% planned within two years) while data access and trust in agent decisions lag badly (average 45% data access, only ~half trust agent outputs). The result is a structural mismatch between platform-vendor momentum and enterprise readiness to actually govern and trust the agents being deployed.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Morgan Stanley & Co. LLC
Same entity (Morgan Stanley & Co. LLC), same metric (net_income), same fiscal period (Q1 2026), same observation date (2026-03-31), but vastly different values: $5.567 billion vs. $5.57. These cannot coexist for the same time period. Fact B appears to be a data entry error (possible missing decimal placement: 5.57 should likely be 5,567,000,000 or a per-share figure incorrectly entered as total).
We flag conflicts openly ›
Recently verified
Checked against the original source
4,979
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,979 facts checked against source5,257 source documents archived
Query this data → isubstrate.com